.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,674,472

« Back to Dashboard

Claims for Patent: 5,674,472

Title: Canisters containing aerosol formulations containing P134a and fluticasone propionate
Abstract:The present invention relates to canisters suitable for delivering a pharmaceutical aerosol formulation which comprises a container capable of withstanding the vapor pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is fluticasone propionate or a physiologically acceptable solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based on the weight of the medicament, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns. A further particulate medicament may also be present in the pharmaceutical aerosol formulation.
Inventor(s): Akehurst; Rachel Ann (Ware, GB3), Taylor; Anthony James (Ware, GB3), Wyatt; David Andrew (Ware, GB3)
Assignee: Glaxo Group Limited (London, GB)
Application Number:08/444,919
Patent Claims: 1. A canister suitable for delivering a pharmaceutical aerosol formulation which comprises a container capable of withstanding the vapor pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is fluticasone propionate or a physiologically acceptable solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based on the weight of the medicament, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.

2. A canister as claimed in claim 1 wherein the container is plastics coated, lacquer-coated or anodized.

3. A canister as claimed in claim 1 wherein the container is a metal can.

4. A canister as claimed in claim 1 wherein the container is a metal can which is plastics-coated.

5. A canister as claimed in claim 1 wherein the container is an aluminum can.

6. A canister as claimed in claim 1 wherein the container is an aluminum can which is plastics-coated.

7. A canister as claimed in claim 1 wherein the particulate medicament is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.

8. A canister as claimed in claim 1 wherein the formulation has a respirable fraction of 20% or more by weight of the particulate medicament.

9. A canister suitable for delivering a pharmaceutical aerosol formulation which comprises a container capable of withstanding the vapor pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation consisting of a particulate medicament consisting of fluticasone propionate or a physiologically acceptable solvate thereof and 1,1,1,2- tetrafluoroethane as propellant, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.

10. A canister as claimed in claim 9 wherein the container is plastics coated, lacquer-coated or anodized.

11. A canister as claimed in claim 9 wherein the container is a metal can.

12. A canister as claimed in claim 9 wherein the container is a metal can which is plastics-coated.

13. A canister as claimed in claim 9 wherein the container is an aluminum can.

14. A canister as claimed in claim 9 wherein the container is an aluminum can which is plastics-coated.

15. A canister as claimed in claim 9 wherein the particulate medicament is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.

16. A canister suitable for delivering a pharmaceutical aerosol formulation which comprises a container capable of withstanding the vapor pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation consisting essentially of: (i) particulate medicament which is fluticasone propionate or a physiologically acceptable solvate thereof; (ii) a particulate medicament selected from the group consisting of salmeterol, salbutamol, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof; and (iii) 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based on the weight of the medicament, the particulate medicaments being present in an amount of 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.

17. A canister suitable for delivering a pharmaceutical aerosol formulation which comprises a container capable of withstanding the vapor pressure of the propellant used, which container is closed with a metering valve and contains (pharmaceutical aerosol formulation consisting of particulate medicament consisting of; (i) fluticasone propionate or a physiologically acceptable solvate thereof; (ii) a particulate medicaments selected from the group consisting of salmeterol, salbutamol, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof; and (iii) 1,1,1,2-tetrafluoroethane as propellant, the particulate medicaments being present in an amount of 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.

18. A canister as claimed in claim 16 or claim 17 wherein the container is plastics-coated, lacquer-coated or anodized.

19. A canister as claimed in claim 16 or claim 17 wherein the container is a metal can.

20. A canister as claimed in claim 16 or claim 17 wherein the container is a metal can which is plastics-coated.

21. A canister as claimed in claim 16 or claim 17 wherein the container is an aluminum can.

22. A canister as claimed in claim 16 or claim 17 wherein the container is an aluminum can, which is plastics-coated.

23. A canister as claimed in claim 16 or claim 17 wherein the particulate medicament is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.

24. A canister as claimed in claim 16 or claim 17 which contains fluticasone propionate or a physiologically acceptable solvate thereof and salmeterol or salbutamol or a physiologically acceptable salt thereof.

25. A canister as claimed in claim 16 or claim 17 which contains fluticasone propionate and salmeterol xinafoate.

26. A metered dose inhaler which comprises a canister as claimed in claim 1 fitted into a channelling device for nasal or oral inhalation of the pharmaceutical aerosol formulation.

27. A metered dose inhaler which comprises a canister as claimed in claim 9 fitted into a channelling device for nasal or oral inhalation of the pharmaceutical aerosol formulation.

28. A metered dose inhaler which comprises a canister as claimed in claim 16 fitted into a suitable channeling device for nasal or oral inhalation of the pharmaceutical aerosol formulation.

29. A metered dose inhaler which comprises a canister as claimed in claim 17 fitted into a suitable channeling device for nasal or oral inhalation of the pharmaceutical aerosol formulation.

30. A canister as claimed in claim 16 wherein the formulation has a respirable fraction of 20% or more by weight of the particulate medicament.

31. A canister suitable for delivering a pharmaceutical aerosol formulation which comprises a container capable of withstanding the vapor pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation consisting essentially of particulate medicament which is fluticasone propionate, and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based on the weight of the medicament, the particulate medicament being present in an amount from 0.01 to 1% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.

32. A canister as claimed in claim 31 wherein the container comprises an aluminum can which is plastics coated.

33. A canister as claimed in claim 31 wherein the formulation is free of surfactant.

34. A canister suitable for delivering a pharmaceutical aerosol formulation which comprises a container capable of withstanding the vapor pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation consisting essentially of particulate medicaments which are fluticasone propionate and salmeterol xinafoate, and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based on the weight of the medicament, the particulate medicaments being present in an amount from 0.01 to 1% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.

35. A canister as claimed in claim 34 wherein the container comprises an aluminum can which is plastics coated.

36. A canister as claimed in claim 34 wherein the formulation is free of surfactant.

37. A canister as claimed in claim 1 wherein the formulation is free of surfactant.

38. A canister as claimed in claim 16 wherein the formulation is free of surfactant.

39. A canister as claimed in claim 1 wherein the particulate medicament is fluticasone propionate.

40. A canister as claimed in claim 9 wherein the particulate medicament is fluticasone propionate.

41. A canister as claimed in claim 1 wherein the formulation is in a form suitable for inhalation into the lungs of a patient.

42. A canister as claimed in claim 9 wherein the formulation is in a form suitable for inhalation into the lungs of a patient.

43. A canister as claimed in claim 16 wherein the formulation is in a form suitable for inhalation into the lungs of a patient.

44. A canister as claimed in claim 17 wherein the formulation is in a form suitable for inhalation into the lungs of a patient.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc